Literature DB >> 18227182

Comparison of lipid amphotericin B preparations in treating murine zygomycosis.

Ashraf S Ibrahim1, Teclegiorgis Gebremariam, Mohamed I Husseiny, David A Stevens, Yue Fu, John E Edwards, Brad Spellberg.   

Abstract

We compared the efficacies of liposomal amphotericin B (LAmB) and an amphotericin B lipid complex (ABLC) in diabetic ketoacidotic (DKA) or neutropenic mice with disseminated zygomycosis. ABLC was as effective as LAmB in neutropenic but not DKA mice. Low-dose ABLC was less effective than LAmB at reducing brain fungal burdens in both models.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18227182      PMCID： PMC2292510          DOI： 10.1128/AAC.01488-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Efficacy of Abelcet alone, or in combination therapy, against experimental central nervous system aspergillosis.

Authors:  Karl V Clemons; Rachana Parmar; Marife Martinez; David A Stevens
Journal:  J Antimicrob Chemother       Date:  2006-06-07       Impact factor: 5.790

2.  Standardization of a fluconazole bioassay and correlation of results with those obtained by high-pressure liquid chromatography.

Authors:  J H Rex; L H Hanson; M A Amantea; D A Stevens; J E Bennett
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

3.  A case of chronic progressive rhinocerebral mucormycosis treated with liposomal amphotericin B and surgery.

Authors:  M Ericsson; M Anniko; H Gustafsson; C A Hjalt; R Stenling; A Tärnvik
Journal:  Clin Infect Dis       Date:  1993-04       Impact factor: 9.079

4.  Rhinocerebral mucormycosis treated with 32 gram liposomal amphotericin B and incomplete surgery: a case report.

Authors:  A A Cagatay; S S Oncü; S S Calangu; T T Yildirmak; H H Ozsüt; H H Eraksoy
Journal:  BMC Infect Dis       Date:  2001-11-23       Impact factor: 3.090

5.  Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system.

Authors:  A H Groll; N Giri; V Petraitis; R Petraitiene; M Candelario; J S Bacher; S C Piscitelli; T J Walsh
Journal:  J Infect Dis       Date:  2000-07-06       Impact factor: 5.226

6.  Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis.

Authors:  Ashraf S Ibrahim; Joel C Bowman; Valentina Avanessian; Keturah Brown; Brad Spellberg; John E Edwards; Cameron M Douglas
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

Review 7.  Improved outcome of zygomycosis in patients with hematological diseases?

Authors:  B Gleissner; A Schilling; I Anagnostopolous; I Siehl; E Thiel
Journal:  Leuk Lymphoma       Date:  2004-07

8.  Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae.

Authors:  Ashraf S Ibrahim; Valentina Avanessian; Brad Spellberg; John E Edwards
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

9.  The iron chelator deferasirox protects mice from mucormycosis through iron starvation.

Authors:  Ashraf S Ibrahim; Teclegiorgis Gebermariam; Yue Fu; Lin Lin; Mohamed I Husseiny; Samuel W French; Julie Schwartz; Christopher D Skory; John E Edwards; Brad J Spellberg
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

10.  Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.

Authors:  T J Walsh; J W Hiemenz; N L Seibel; J R Perfect; G Horwith; L Lee; J L Silber; M J DiNubile; A Reboli; E Bow; J Lister; E J Anaissie
Journal:  Clin Infect Dis       Date:  1998-06       Impact factor: 9.079
View more
  17 in total

1.  Efficacy of liposomal amphotericin B and posaconazole in intratracheal models of murine mucormycosis.

Authors:  Guanpingsheng Luo; Teclegiorgis Gebremariam; Hongkyu Lee; Samuel W French; Nathan P Wiederhold; Thomas F Patterson; Scott G Filler; Ashraf S Ibrahim
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

Review 2.  Diagnosis and treatment of invasive fungal infections focus on liposomal amphotericin B.

Authors:  João F Lacerda; Carlos Meneses Oliveira
Journal:  Clin Drug Investig       Date:  2013-02       Impact factor: 2.859

3.  Stability in the cumulative incidence, severity and mortality of 101 cases of invasive mucormycosis in high-risk patients from 1995 to 2011: a comparison of eras immediately before and after the availability of voriconazole and echinocandin-amphotericin combination therapies.

Authors:  Maheen Z Abidi; Muhammad R Sohail; Nathan Cummins; Mark Wilhelm; Nancy Wengenack; Lisa Brumble; Harshal Shah; Donna Jane Hata; Ann McCullough; Amy Wendel; Holenarasipur R Vikram; Shimon Kusne; Mark Litzow; Louis Letendre; Brian D Lahr; Eric Poeschla; Randall C Walker
Journal:  Mycoses       Date:  2014-07-18       Impact factor: 4.377

Review 4.  Human Fungal Pathogens of Mucorales and Entomophthorales.

Authors:  Leonel Mendoza; Raquel Vilela; Kerstin Voelz; Ashraf S Ibrahim; Kerstin Voigt; Soo Chan Lee
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-06       Impact factor: 6.915

5.  Pros and Cons of Extrapolating Animal Data on Antifungal Pharmacodynamics to Humans.

Authors:  Scott W Mueller; Tyree H Kiser
Journal:  Curr Fungal Infect Rep       Date:  2011-03-26

6.  Recent advances in the treatment of mucormycosis.

Authors:  Brad Spellberg; Ashraf S Ibrahim
Journal:  Curr Infect Dis Rep       Date:  2010-11       Impact factor: 3.725

Review 7.  Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.

Authors:  Marit D Moen; Katherine A Lyseng-Williamson; Lesley J Scott
Journal:  Drugs       Date:  2009       Impact factor: 9.546

8.  Efficacy of liposomal amphotericin B combined with gamma interferon or granulocyte-macrophage colony-stimulating factor for treatment of systemic zygomycosis in mice.

Authors:  M Mar Rodríguez; Enrique Calvo; Marçal Mariné; F Javier Pastor; Joan Fernandez-Ballart; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

Review 9.  Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3).

Authors:  Anna Skiada; Fanny Lanternier; Andreas H Groll; Livio Pagano; Stephan Zimmerli; Raoul Herbrecht; Olivier Lortholary; George L Petrikkos
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

Review 10.  Recent advances in the management of mucormycosis: from bench to bedside.

Authors:  Brad Spellberg; Thomas J Walsh; Dimitrios P Kontoyiannis; John Edwards; Ashraf S Ibrahim
Journal:  Clin Infect Dis       Date:  2009-06-15       Impact factor: 9.079
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.